Aratana Therapeutics Inc. (NASDAQ:PETX) saw strong trading volume on Tuesday . 1,203,807 shares were traded during mid-day trading, an increase of 24% from the previous session’s volume of 972,851 shares.The stock last traded at $9.02 and had previously closed at $9.41.

Several equities analysts have issued reports on the stock. Barclays PLC cut their price target on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday. Credit Suisse Group AG reissued a “buy” rating and set a $11.00 price objective on shares of Aratana Therapeutics in a report on Wednesday, August 10th. Finally, Lake Street Capital reissued a “buy” rating and set a $15.00 price objective on shares of Aratana Therapeutics in a report on Sunday, July 17th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $11.16.

The firm’s market capitalization is $318.91 million. The stock’s 50-day moving average price is $7.44 and its 200-day moving average price is $5.91.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.37. The firm earned $38.05 million during the quarter, compared to analyst estimates of $15.14 million. During the same quarter in the previous year, the business posted ($0.23) earnings per share. Analysts anticipate that Aratana Therapeutics Inc. will post ($0.73) EPS for the current fiscal year.

In other Aratana Therapeutics news, insider Julia A. Stephanus sold 30,000 shares of the firm’s stock in a transaction on Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total transaction of $187,500.00. Following the transaction, the insider now directly owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total transaction of $462,500.00. Following the transaction, the insider now directly owns 642,793 shares in the company, valued at $5,945,835.25. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.